The potential use of selective 5-HT2C agonists in treating obesity

Expert Opinion on Investigational Drugs

Volumn 15, Issue 3, 2006, Pages 257-266

  Smith, Brian M ^a   Thomsen, William J ^a   Grottick, Andrew J ^a  

^a ARENA PHARMACEUTICALS   (United States)

Author keywords

5 HT2C receptor; 5 HT2C agonists; 5 hydroxytryptamine; APD 356; Obesity; Weight loss

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 1,2,3,4,5,6 HEXAHYDRO 6 METHYLAZEPINO[3,4 B]INDOLE; 2 (6 CHLORO 5 FLUORO 1 INDOLYL) 1 METHYLETHYLAMINE; AMINOREX; AMPHETAMINE; AMPHETAMINE DERIVATIVE; ANOREXIGENIC AGENT; ANTIOBESITY AGENT; APD 356; BVT 933; CHLORPROMAZINE; DEXFENFLURAMINE; FENFLURAMINE; IL 639; LY 448100; METHAMPHETAMINE; NORFENFLURAMINE; PHENTERMINE; PSYCHEDELIC AGENT; RIMONABANT; SEROTONIN 2C AGONIST; SEROTONIN 2C RECEPTOR; SIBUTRAMINE; TETRAHYDROLIPSTATIN; UNCLASSIFIED DRUG; VR 1065; WAY 161503; WAY 163909;

ABSENCE OF SIDE EFFECTS; ANXIETY DISORDER; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONSTIPATION; DECREASED APPETITE; DEFECATION DISORDER; DEFECATION URGENCY; DEPRESSION; DIARRHEA; DISORIENTATION; DIZZINESS; DRUG BRAIN LEVEL; DRUG DEPENDENCE; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DYSPHORIA; EUPHORIA; EVIDENCE BASED MEDICINE; FOOD INTAKE; GASTROINTESTINAL SYMPTOM; HEART PALPITATION; HEART VALVE REGURGITATION; HUMAN; HYPERTENSION; INSOMNIA; MOLECULAR DYNAMICS; NAUSEA; NONHUMAN; OBESITY; PULMONARY HYPERTENSION; RESTLESSNESS; REVIEW; SATIETY; TACHYCARDIA; TREMOR; VALIDATION PROCESS; WEIGHT REDUCTION; XEROSTOMIA;

ANIMALS; ANTI-OBESITY AGENTS; CLINICAL TRIALS; DRUGS, INVESTIGATIONAL; HUMANS; OBESITY; RECEPTOR, SEROTONIN, 5-HT2C; SEROTONIN AGONISTS;

EID: 33644772628     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.15.3.257     Document Type: Review

References (56)

1. FLEGAL KM, CARROLL MD, OGDEN CL, JOHNSON CL: Prevalence and trends in obesity among US adults, 1999-2000. J. Am. Med Assoc. (2002) 288(14):1723-1727.
2. NATIONAL TASK FORCE ON THE PREVENTION AND TREATMENT OF OBESITY. Overweight, obesity, and health risk. Arch. Intern. Med. (2000) 160:898-904.
3. MOKDAD AH, MARKS JS, STROUP DF, GERBERDING JL: Actual causes of death in the United States, 2000. J. Am. Med. Assoc. (2004) 291(10):1238-1245.
4. YUSEF S, HAWKEN S, OUNPUU S et al.: Obesity and the risk of myocardial infarction in 27000 participants from 52 countries: a case-control study. Lancet (2005) 366:1640-1649.
5. KLEIN S: Outcome success in obesity. Obes. Res. (2001) 9:354S-358S.
6. COLMAN E: Anorectics on trial: a half century of federal regulation of prescription appetite suppressants. Ann. Intern. Med. (2005) 143:380-385.
7. LE DOUAREC JC, SCHMITT H: Comparison pharmacologique de sept medicaments anorexiques. Therapie (1964) 19:831-841.
8. DUHAULT J, VERDAVAINNE C: Modification du taux de serotonine cerebrale chez le rat par les trifluoromethyl-phenyl-2-ethyl-aminopropane (fenfluramine 768 S). Arch. Int. Pharmacodyn. Ther. (1967) 170:276-286.
9. HALFORD JCG, HARROLD JA, LAWTON CL, BLUNDELL JE: Serotonin (5-HT) drugs: effects on appetite expression and use for the treatment of obesity. Curr. Drug Targets (2005) 6:201-213.
10. CLIFTON PG: Meal patterning in rodents: psychopharmacological and neuroanatomical studies. Neurosci. Biobehav. Rev. (2000) 24:213-222.
11. FOTLIN RW, HANEY M, COMER SD, FISCHMAN MW: Effect of fenfluramine on food intake, mood, and performance of humans living in a residential laboratory. Physiol. Behav. (1996) 59(2):295-305.
12. HOYER D, HANNON JP, MARTIN GR: Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol. Biochem. Behav. (2002) 71:533-554.
13. 2C receptor agonists: Potential for the treatment of obesity. Mol. Int. (2005) 5(5):282-291.
14. 2c receptors. Neuropharmacology (2001) 41(2):200-209.
15. 2c receptor agonists: Pharmacological characteristics and therapeutic potential. J. Pharmacol. Exp. Ther. (1998) 286:913-924.
16. 2C receptor agonists as potential drugs for the treatment of obesity. Curr. Top. Med. Chem. (2003) 3:885-897.
17. 2C receptor mutant mice. Psychopharmacology (1999) 143(3):309-314.
18. 2C serotonin receptors. Nature (1995) 374:542-546.
19. CONNOLLY HM, CRARY JL, McGOON MD et al.: Valvular heart disease associated with fenfluramine-phentermine. N. Engl. J. Med (1997) 337(9):581-588.
20. FITZGERALD LW, BURN TC, BROWN BS et al.: Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine Mol. Pharm. (2000) 57(1):75-81.
21. ROTHMAN RB, BAUMANN MH, SAVAGE JE et al: Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation (2000) 102(23):2836-2841.
22. SETOLA V, ROTH BL: Screening the receptorome reveals molecular targets responsible for drug-induced side effects: focus on 'fen-phen.' Expert Opin. Drug Metab. Toxicol. (2005) 1(3):377-387.
23. GUSTAFSSON BI, TOMMERAS K, NORDRUM I et al: Long term serotonin administration induces heart valve disease in rats. Circulation (2005) 111:1517-1522.
24. FISHMAN AP: Aminorex to fen/phen. An epidemic foretold. Circulation (1999) 99:156-161.
25. ABENHAIM L, MORIDE Y, BRENOT F et al: Appetite-suppressant drugs and the risk of pulmonary hypertension. N. Engl, J. Med (1996) 335(9):609-616.
26. RICH S, RUBIN L, WALKER AM et al: Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension. Chest (2000) 117:870-874.
27. MacLEAN MR, HERVE P, EDDAHIBI S, ADNOT S: 5-Hydroxytryptamine and the pulmonary circulation: receptors, transporters and relevance to pulmonary arterial hypertension. Br. J. Pharmacol. (2000) 131:161-168.
28. LUANAY JM, HERVE P, PEOC'H K et al: Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat. Med. (2002) 8(10):1129-1135.
29. MARCOS E, FADEL E, SANCHEZ O et al: Serotonin-induced smooth muscle hyperplasia in various forms of human pulmonary hypertension. Circ, Res. (2004) 94:1263-1270.
30. NICHOLS DE: Hallucinogens. Pharmacol, Behav. (2004) 101:131-181.
31. FONE KC, JOHNSON JV, BENNETT GW, MARSDEN CA: Involvement of 5-HT2 receptors in the behaviours produced by intrathecal administration of selected 5-HT agonists and the TRH analogue (CC 3509) to rats. Br. J. Pharmacol (1989) 96:599-608.
32. 2C receptor agonists. Expert Opin. Ther. Patents (2003) 13(11):1691-1705.
33. 2C receptors in affective disorders. Expert Opin. Invest. Drugs (1998) 7(10):1587-1599.
34. 2C receptor agonists. Bioorg. Med. Chem. Lett. (2004) 14:2367-2370.
35. 2C receptor agonists. Abstracts of Papers, 230th ACS National Meeting. Washington, DC, USA (28 August - 1 September 2005).
36. 2C receptor agonists for the treatment of obesity. Biological and chemical adventures. Chimia (2004) 58(9):613-620.
37. 2C receptor agonist precursor. Org. Proc. Res. Dev. (2005) 9(4):508-512.
38. 2C agonist Way-161503. FASEB J. (2000) 14:A1321.
39. WELMAKER GS, NELSON JA, SABALSKI JE et al: Synthesis and 5-hydroxytryptamine (5HT) activity of 2,3,4,4a-tetrahydro-1H-pyrazino[ 1,2-a] quinoxalin-5-(6H)ones and 2,3,4,4a,5,6-hexahydro-1H-pyrazino[1,2-a] quinoxalines. Bioorg. Med Chem. Lett. (2000) 10:1991-1994.
40. DUNLOP J, SABB AL, MAZANDARANI H et al: WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro7bH-cyclopenta-[b] [1,4]diazepino[6,7,1hi] indole, a novel 5-hydroxytryptamine 2C receptor-selective agonist with anorectic activity. J. Pharmaco. Exp. Ther, (2005) 313(2):862-869.
41. 2C receptor agonists for the treatment of obesity. Abstracts of Papers, 221st ACS National Meeting, San Diego, USA (1 - 5 April 2001).
42. 2C receptor agonists provide anti-obesity drugs. Metabolic Diseases Drug Discovery World Summit, San Diego, USA (29 July 2003).
43. HESTER JB, TANG AH, KEASLING HH, VELDCAMP W: Azepineindoles. I. Hexahydroazepino[4,5-b]indoles. J. Med. Chem. (1968) 11:101-106.
44. GALLANT DM, BISHOP MP, BISHOP G, O'MEALLIE L: U-22,394A: A controlled evaluation in chronic schizophrenic patients. Curr. Ther. Res. (1967) 9:579-581.
45. 2C receptor agonist, reduces feeding in rodents and produces weight loss in humans. Abstracts of Papers, 31st Soc. Neurosci. Meeting, San Diego, USA (2001) 27:309.2.
46. WALSH AE, SMITH KA, OLDMAN AD: m-Chlorophenylpiperazine decreases food intake in a test meal. Psychopharmacology (1994) 116:120-122.
47. COWEN PJ, SARGENT PA, WILLIAMS C, GOODALL EM, OLIKOV AB: Hypophagic, endocrine and subjective responses to m-chlorophenylpiperazine in healthy men and women. Hum. Psychopharmacol. (1995) 10:385-391.
48. 2C receptor activation decreases appetite and body weight in obese subjects. Psychopharmacology (1997) 133:309-312.
49. VAN GAAL LF, RISSANEN AM, SCHEEN AJ ZIEGLER O, ROSSNER S: Effects of the cannabinoid-I receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet (2005) 365:1389-1397.
50. HADDOCK CK, POSTON WSC, DILL PL FOREYT JP, ERICSSON M: Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int. J. Obes. (2002) 26:262-273.
51. THOMSON HEALTHCARE: Product information: adipex-P. In: Physicians' Desk Reference. Medical Economics Company, Montvale, USA (2002):1406-1407.
52. DESPRES JP, GOLAY A, SJOSTROM L: Effects of Rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N. Engl. J. Med. (2005) 353(20):2121-2134.
53. JANDACEK RJ: APD356 Arena. Curr. Opin. Invest. Drugs (2005) 6(10):1051-1056.
54. 2C receptor agonists for the treatment of obesity. Bioorg. Med. Chem. Lett. (2005) 15:1467-1470.
55. 2C receptor agonists for the treatment of obesity. Abstracts of Papers, 229th ACS National Meeting, San Diego, USA (13-17 March 2005).
56. BLANCK HM, KHAN LK, SERDULA MK: Prescription weight loss pill use among Americans: patterns of pill use and lessons learned from the fen-phen market withdrawal. Preventive Med. (2004) 39:1243-1248.